Esperion Therapeutics Q2 2025 Earnings Report

Esperion Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.17
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Esperion Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $62.55 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Esperion Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/11/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Esperion Therapeutics (NASDAQ:ESPR) is a U.S.-based biopharmaceutical company dedicated to the discovery, development and commercialization of orally administered therapies designed to lower low-density lipoprotein cholesterol (LDL-C) in patients at risk for cardiovascular disease. Originally founded in 1998 and later acquired by Pfizer in 2004, the company was re-established as an independent public entity in 2013 after securing the rights to its proprietary assets. Headquartered in Ann Arbor, Michigan, Esperion combines scientific innovation with a targeted clinical development strategy to address the persistent unmet needs in lipid management.

The company’s lead products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid/ezetimibe), represent the first new oral non-statin treatments approved in the United States and European Union for patients with hypercholesterolemia. By inhibiting ATP-citrate lyase, these therapies offer an alternative mechanism to statins and have demonstrated significant LDL-C reductions in both monotherapy and combination settings. Esperion’s pipeline further includes next-generation compounds aimed at improving cardiovascular outcomes and expanding treatment options for high-risk patient populations.

Esperion’s global footprint spans North America and Europe, supported by a commercial infrastructure in the United States and strategic partnerships to facilitate market access abroad. The company engages with regulatory authorities, healthcare providers and patient advocacy groups to advance its mission of reducing cardiovascular risk. Ongoing clinical programs explore additional indications and broader patient cohorts, reflecting Esperion’s commitment to scientific rigor and patient-centric development.

Under the leadership of President and Chief Executive Officer Dr. Martin J. Braddock, Esperion draws on a management team with deep experience in cardiovascular drug development and commercialization. The company’s strategic priorities include strengthening its market presence, accelerating pipeline advancement and forging collaborations to harness emerging scientific insights. Through its focused approach, Esperion aims to establish a new standard of care for patients with elevated cholesterol and cardiovascular disease risk.